Discovery of an evolutionarily distinct evasin with dual CC and CXC chemokine inhibitory activity
Structure · 2026
DOI: 10.1016/j.str.2026.02.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Structure, 2026. Verfasst von Surendra Kunwar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia. Hauptthemen laut MEDLINE: Chemokines, CXC, Chemokines, CC. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Research to Prevent Blindness, Ocean University of China.
Abstract (Originalsprache)
Chemokine-driven leukocyte trafficking is central to the pathogenesis of cancer and autoimmune/inflammatory diseases. Therapeutic targeting of the chemokine system has largely failed due to promiscuous binding between chemokines and their receptors. Blood-feeding ticks evade immune responses by secreting salivary evasins that selectively bind and neutralize either CC or CXC chemokines. Here, we describe EVA-ATL1001 (EVA-ATL), an evasin with dual CC/CXC inhibitory function. Like other class A evasins, EVA-ATL engages CC chemokines through conserved hydrogen bonds between its β1 region and the chemokine CC motif. Remarkably, the same interface accommodates CXC chemokines with minor structural adjustments. This dual recognition is mediated primarily by a shallow hydrophobic pocket, along with contributions from the N-terminus and β1-β2 region, features absent in other evasins. EVA-ATL represents a natural evasin with broad-spectrum CC/CXC chemokine inhibition, offering a promising framework for next-generation immunotherapeutics for complex pathologies involving both chemokine families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
- Department of Physiology and Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
- Key Laboratory of Marine Drugs Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6140, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1142, New Zealand.
- School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia; Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Au…
- Department of Biochemistry and Molecular Biology and Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia. Electronic address: martin.stone@monash.edu.
Förderung
- China Scholarship Council
- Research to Prevent Blindness
- Ocean University of China
- National Health and Medical Research Council
Zitieren
APA
Kunwar, S., Devkota, S. R., Ang, C., Aryal, P., Gai, W., Pokhrel, R., So, S. S., Jiao, W., Payne, R. J., Robert, R., Stone, M. J., & Bhusal, R. P. (2026). Discovery of an evolutionarily distinct evasin with dual CC and CXC chemokine inhibitory activity. Structure. https://doi.org/10.1016/j.str.2026.02.001
Vancouver
Kunwar S, Devkota SR, Ang C, Aryal P, Gai W, Pokhrel R, et al. Discovery of an evolutionarily distinct evasin with dual CC and CXC chemokine inhibitory activity. Structure. 2026. doi:10.1016/j.str.2026.02.001
BibTeX
@article{Kunwar2026,
author = {Kunwar, Surendra and Devkota, Shankar Raj and Ang, Caroline and Aryal, Pramod and Gai, Wenrui and Pokhrel, Rina and So, Sean S and Jiao, Wanting and Payne, Richard J and Robert, Remy and Stone, Martin J and Bhusal, Ram Prasad},
title = {Discovery of an evolutionarily distinct evasin with dual CC and CXC chemokine inhibitory activity},
journal = {Structure},
year = {2026},
doi = {10.1016/j.str.2026.02.001}
}
EUVIMED